G. Rustin

A. Oza, G. Rustin, R. Buckanovich, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.

M. Gore, G. Rustin, H. Gabra, 2010, European journal of cancer.

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials).

G. Rustin, M. van der Burg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials).

G. Rustin, M. van der Burg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).

G. Jayson, G. Rustin, H. Gabra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lactate dehydrogenase is not a useful marker for relapse in patients on surveillance for stage I germ cell tumours

G. Rustin, C. Ackers, 2006, British Journal of Cancer.

How long should first-line chemotherapy continue?

G. Rustin, S. Grénman, K. Bertelsen, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

State-of-the-art approach in selective curable tumors: germ cell tumors.

G. Rustin, F. Rehman, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients.

D. Berney, J. Shamash, G. Rustin, 2020, European journal of cancer.

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma* A Ovary

W. Gregory, G. Rustin, A. Nelstrop, 2005 .

Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome

G. Rustin, H. Gabra, M. Hall, 2019, Annals of Surgical Oncology.

No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.

G. Rustin, C. Landen, R. Buckanovich, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

G. Rustin, I. Vergote, C. Pippitt, 2010 .

A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982.

G. Rustin, G. Mead, P. Ell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

R. Laing, R. Huddart, M. Highley, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of carboplatin AUC-10 guided by positron emission tomography-defined metabolic response in metastatic seminoma.

J. Shamash, G. Rustin, R. Syed, 2019, European journal of cancer.

Management of Non-Epithelial Ovarian Tumours

G. Rustin, J. Bridgewater, 1999, Oncology.

Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.

J. Ledermann, G. Rustin, M. Friedlander, 2006, Gynecologic oncology.

The cost of surveillance following treatment of ovarian cancer.

G. Rustin, 2013, Gynecologic oncology.

Controversies in the management of germ cell tumours of the ovary

G. Rustin, D. Patterson, 2006, Current opinion in oncology.

Fertility after chemotherapy for ovarian germ cell tumours

G. Rustin, D. Pektasides, E. Newlands, 1988, British journal of obstetrics and gynaecology.

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

M. Gore, G. Rustin, R. Beckman, 2001, British Journal of Cancer.

Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).

M. Gore, J. Ledermann, G. Rustin, 2015 .

Audit of CA 125 Follow-Up After First-Line Therapy for Ovarian Cancer

G. Rustin, M. Hall, S. Benafif, 2017 .

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.

D. Kerr, G. Rustin, N. Bleehen, 1989, British Journal of Cancer.

Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4).

G. Rustin, H. Gabra, P. Vasey, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASA404: update on drug development.

G. Rustin, F. Rehman, 2008, Expert opinion on investigational drugs.

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

A. Harris, D. Collins, A. Padhani, 2012, Clinical Cancer Research.

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results.

G. Jayson, G. Rustin, M. Zweifel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pacfitaxel (Taxol) inrelapsed andrefractory ovarian cancer:theUK and Eireexperience

G. Rustin, A. Calvert, V. Lévy, 1995 .

A North-West London Experience of the Impact of Treatment Related Toxicity on Clinical Outcomes of Elderly Patients with Germ Cell Tumors

G. Rustin, N. Vasdev, Aruni Ghose, 2022, Cancers.

Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased.

G. Rustin, F. Paradinas, B. Wignall, 1989, European journal of cancer & clinical oncology.

Potential Use of Retinoids in Cancer Prevention and Treatment

G. Rustin, 1984 .

Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment.

G. Rustin, I. McNeish, R. Agarwal, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced malignant melanoma with interferon alpha and etretinate.

G. Rustin, S. Dische, A. Nelstrop, 1988, European journal of cancer & clinical oncology.

Mixed germ cell tumour arising from abdominal testicular tissue after apparent orchidectomy

T. Christmas, G. Rustin, R. Miano, 2001, BJU international.

Progress in the management of gynecologic cancer: consensus summary statement.

R. Bast, S. Skates, J. Garber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

D. Collins, A. Padhani, D. Koh, 2015, The oncologist.

HTLV-1 associated T-cell lymphoma in a patient with a 10-year history of non-epidermotropic T-cell skin infiltrates.

G. Rustin, F. Paradinas, K. Tonkin, 1990, Clinical oncology (Royal College of Radiologists (Great Britain)).

Management of brain metastases in patients with high-risk gestational trophoblastic tumors.

G. Rustin, I. McNeish, M. Seckl, 2002, The Journal of reproductive medicine.

Phase I study of intravenous 4-hydroxyanisole.

P. Philip, G. Rustin, A. Lamont, 1992, European journal of cancer.

No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors.

G. Rustin, K. Bagshawe, J. Dent, 1983, The New England journal of medicine.

The Clinical Value of Tumour Markers in the Management of Ovarian Cancer

G. Rustin, 1996, Annals of clinical biochemistry.

Managing malignant ovarian germ cell tumours.

G. Rustin, 1987, British medical journal.

Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).

G. Rustin, G. Mead, R. Coleman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgery and chemotherapy in the management of placental site tumor.

G. Rustin, F. Paradinas, K. Bagshawe, 1990, Gynecologic oncology.

Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years.

G. Rustin, E. Newlands, M. Bower, 1998, European journal of cancer.

Gestational trophoblastic disease with liver metastases: the Charing Cross experience

G. Rustin, R. A’Hern, E. Newlands, 1997, British journal of obstetrics and gynaecology.

Diagnostic delay and risk of relapse in patients with stage I nonseminomatous germ cell tumour followed on active surveillance

G. Rustin, M. Napier, 2000, BJU international.

Vascular damaging agents.

G. Rustin, G. Rustin, D. Patterson, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.

Martin A Lodge, R. Maxwell, A. Padhani, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Michael Thomas, G. Rustin, N. Lemoine, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

D. Matei, J. Ledermann, C. Scott, 2016, The Lancet. Oncology.

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

R. Plummer, G. Rustin, M. Friedlander, 2016, Targeted Oncology.

Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Werner Meier, Ignace Vergote, Philipp Harter, 2016, Cancer.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

D. Matei, J. Ledermann, J. Barrett, 2014 .

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

M. Parmar, E. Eisenhauer, G. Rustin, 2000, Journal of the National Cancer Institute.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

M. Parmar, E. Eisenhauer, J. Ledermann, 2016, The Lancet.

Epithelial ovarian cancer: a review of current management.

G. Rustin, P. Nathan, G. Rustin, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

Molecular and biological factors in the pathogenesis of ovarian cancer.

G. Rustin, J. Berek, C. Tropé, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

M. Duffy, G. Rustin, M. Duffy, 2004, International Journal of Gynecologic Cancer.

Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer

J. Ledermann, G. Jayson, G. Rustin, 2010, Clinical Cancer Research.

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.

M. Piccart, E. Eisenhauer, G. Rustin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trials in ovarian carcinoma: study methodology.

M. Parmar, E. Eisenhauer, G. Rustin, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer

R. Bast, G. Rustin, C. Sigman, 2004, Clinical Cancer Research.

Use of CA-125 to assess response to new agents in ovarian cancer trials.

G. Rustin, Gordon J S Rustin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer

G. Rustin, M. Hall, S. Benafif, 2017, International Journal of Gynecologic Cancer.

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer

G. Rustin, P. Vasey, S. Kaye, 2006, British Journal of Cancer.

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer

G. Rustin, M. Seckl, R. Agarwal, 2004, British Journal of Cancer.

CA125 response: can it replace the traditional response criteria in ovarian cancer?

G. Rustin, A. Guppy, 2002, The oncologist.

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels.

G. Rustin, T. Meyer, M. Marples, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

U s e o f CA-125 t o D efine P rogression o f O varian C ancer i n Patients W ith P ersistently E levated L evels

G. Rustin, T. Meyer, M. Marples, 2001 .

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.

M. Gore, G. Rustin, J. Bridgewater, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Jacobus Pfisterer, Gordon C Jayson, Michael Quinn, 2015, The Lancet. Oncology.

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

M. Gore, G. Rustin, H. Gabra, 2008, British Journal of Cancer.

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

E. Trimble, M. Parmar, E. Eisenhauer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer

D. Alberts, B. Monk, R. Bast, 2010 .

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.

A. Padhani, G. Rustin, M. Lodge, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.

Y. Drew, R. Plummer, M. Ranson, 2012 .

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.

G. Jayson, G. Rustin, C. Dive, 2020, Gynecologic oncology.

Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application

Stephen Townsend, Judith Parker, Matthew Sydes, 2019, Clinical trials.

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

N. Bleehen, G. Rustin, N. Bleehen, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Clinical Development of Tubulin Binding Vascular Disrupting Agents

G. Rustin, M. Zweifel, 2010 .

Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials.

G. Rustin, S. Bentzen, S. Bond, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.

J. Ledermann, R. Glasspool, G. Rustin, 2020, Gynecologic oncology.

Targeted anti-vascular therapies for ovarian cancer: current evidence

J Ledermann, M. Gore, J. Ledermann, 2013, British Journal of Cancer.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

B. Monk, A. Oza, R. Wenham, 2017, European journal of cancer.

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

D. Matei, J. Ledermann, C. Scott, 2018, British Journal of Cancer.

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

G. Jayson, M. Sawyer, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A Qualitative Analysis of the Impact of Carboplatin AUC 10 on Physical, Work Functioning and Bone Marrow Toxicity Among Seminoma Patients – A Single-centre Experience

G. Rustin, M. Hall, M. Milić, 2018, In Vivo.

Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities

G. Rustin, H. Gabra, S. Brett, 2016, Archives of Gynecology and Obstetrics.

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

G. Jayson, G. Rustin, M. Zweifel, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

T. Ganesan, G. Rustin, P. Nathan, 2010, British Journal of Cancer.

A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas

A. Padhani, G. Rustin, T. Meyer, 2009, Clinical Cancer Research.

A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas

A. Padhani, G. Rustin, T. Meyer, 2009, Clinical Cancer Research.

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

G. Rustin, N. Thatcher, Y. Summers, 2002, Melanoma research.

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

M. Gore, G. Jayson, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of temozolomide using an extended continuous oral schedule.

M. Roddie, G. Rustin, E. Newlands, 1998, Cancer research.

A phase Ib trial of combretastatin A- 4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer

T. Ganesan, G. Rustin, P. Nathan, 2005 .

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

S. Halford, P. Price, A. Padhani, 2012, Clinical Cancer Research.

3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.

E. Trimble, M. Parmar, E. Eisenhauer, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Current controversies in the management of germ cell ovarian tumours

G. Rustin, I. Vázquez, 2013, Current opinion in oncology.

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer.

A. Oza, M. Gore, J. Carmichael, 2002, European journal of cancer.

Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer.

M. Gore, R. Glasspool, S. Halford, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.

M. Parmar, A. Oza, J. Ledermann, 2017 .

Diffusion-weighted MR imaging of female pelvic tumors: a pictorial review.

Gordon Rustin, A. Padhani, G. Rustin, 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

D. Matei, J. Ledermann, C. Scott, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Do Not Give Up

G. Rustin, M. Hall, M. Zweifel, 2015, International Journal of Gynecologic Cancer.

ASA404: update on drug development

G. Rustin, F. Rehman, 2008 .

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

M. Parmar, A. Oza, J. Ledermann, 2021, ESMO open.

Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO.

R. Bast, A. Berchuck, G. Rustin, 2000, European journal of gynaecological oncology.

A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).

A R Padhani, A. Padhani, G. Rustin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

H. Earl, M. Gore, J. Ledermann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brampton, M, Stevens MFG. Cancer Research Campaign phase-II trial of temozolomide in malignant melanoma

G. Rustin, N. Bleehen, E. Newlands, 1995 .

RISK OF CANCER IN RELATIVES OF PATIENTS WITH CUTANEOUS MELANOMA

R. Houlston, G. Rustin, M. Rustin, 1993, International journal of dermatology.

Attempted preservation of one gonad in patients with bilateral germ cell tumours.

G. Rustin, P. Gomes, 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer

R. Huddart, G. Rustin, G. Mead, 2018, Clinical genitourinary cancer.

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

G. Rustin, I. Vergote, L. Dirix, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance erlotinib (E) following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian carcinoma

M. Gore, G. Rustin, H. Gabra, 2007 .

FaFEC: a novel regimen for advanced ovarian cancer.

G. Rustin, M. Bower, K. Goodchild, 1997, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

A. Harris, G. Rustin, D. Link, 2009, Cancer research.

Novel presentation of retroperitoneal germ cell tumor with loss of ejaculation but preservation of erection in two patients.

G. Rustin, Claire A Stark Toller, 2005, Fertility and sterility.

Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours

P. Price, A. Padhani, G. Rustin, 2007 .

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy

J. Ledermann, G. Rustin, U. Matulonis, 2015 .

A phase I/II trial of radioimmunotherapy with (131)Iodine labelled A5B7 anti-CEA antibody (I-131-A5B7) in combination with Combretastatin-A4-Phosphate (CA4P) in advanced gastrointestinal carcinomas

A. Padhani, G. Rustin, T. Meyer, 2008 .

Phase I evaluation of vascular disrupting agent OXi4503

P. Price, G. Rustin, M. Stratford, 2008 .